INTS 10-Q: SEC filing
Intensity Therapeutics
Filed with the SEC on · accession 0001567264-26-000066
INTS filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -13.2% by the first close after the filing.
Summary of the filing
Intensity Therapeutics filed its quarterly report on Form 10-Q for the period ending September 30, 2026, accompanied by the CEO's Sarbanes-Oxley Section 302 certification.
Key details
How INTS stock reacted
Close before
$3.57
Nov 4, 2026
First close after
-13.17%
$3.10
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for INTS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for INTS?
Click hereFrequently asked questions
What did INTS file with the SEC on Nov 5, 2026?
INTS filed a 10-Q (SEC filing). Intensity Therapeutics filed its quarterly report on Form 10-Q for the period ending September 30, 2026, accompanied by the CEO's Sarbanes-Oxley Section 302 certification.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did INTS stock react to this filing?
INTS closed at $3.57 before the filing and $3.10 on Nov 5, 2026 (-13.17%).
Other INTS SEC filings
Get alerts when INTS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days